Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade

BACKGROUND: Development of novel agents targeting the androgen axis has led to improved overall survival in castration-resistant prostate cancer (CRPC). This study aimed to investigate the optimal timing of treatment with one such agent, abiraterone acetate (AA), in Japanese patients. MATERIALS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Takashi, Naiki, Taku, Iida, Keitaro, Etani, Toshiki, Ando, Ryosuke, Hamamoto, Shuzo, Sugiyama, Yosuke, Akita, Hidetoshi, Kubota, Hiroki, Hashimoto, Yoshihiro, Kawai, Noriyasu, Yasui, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857185/
https://www.ncbi.nlm.nih.gov/pubmed/29556485
http://dx.doi.org/10.1016/j.prnil.2017.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857185/
https://www.ncbi.nlm.nih.gov/pubmed/29556485
http://dx.doi.org/10.1016/j.prnil.2017.07.001

Ejemplares similares